Being told your knee is “bone-on-bone” often feels like a verdict. The cartilage is gone, the X-ray is clear, and surgery is presented as the next logical step. But a growing number of patients — particularly those in their 50s and 60s, or those with significant health risks that complicate surgery — are asking a different question first: is there anything worth trying before we get to that point?

At EDNA Wellness in Bangkok, this is one of the most common consultations we receive from patients. The answer is not a blanket yes. But for the right patient profile, mesenchymal stem cell therapy represents a clinically considered option worth evaluating before committing to joint replacement.

What “bone-on-bone” actually means clinically

Bone-on-bone is a lay term for Grade III–IV knee osteoarthritis, classified using the Kellgren-Lawrence (KL) scale. At KL Grade III, there is significant joint space narrowing and cartilage damage. At Grade IV, the space is effectively gone — subchondral bone is in direct contact. The pain, stiffness, and loss of function follow.

What patients are rarely told is that structural severity on imaging does not always correlate cleanly with functional symptoms. A 2015 study published in Radiology found that a significant portion of patients with severe radiographic OA reported moderate or manageable pain levels, while others with mild imaging findings were severely limited. This matters because surgery decisions based on X-ray severity alone may not capture what a patient actually needs.

Why some patients delay or avoid surgery

Total knee replacement (TKR) is an effective intervention for end-stage osteoarthritis, and we do not discourage it when it is clinically warranted. However, there are well-documented reasons why many patients explore alternative options before proceeding with surgery.

Implant lifespan is finite. Most knee replacements last approximately 15–20 years, meaning that a patient who undergoes surgery at age 55 may statistically face the possibility of revision surgery later in life. Revision TKR is generally more complex, associated with higher complication rates, and often produces less predictable outcomes compared to a primary replacement.

Surgical risk profiles also vary significantly between individuals. Patients with cardiovascular disease, obesity, diabetes, or other chronic medical conditions may face elevated perioperative and postoperative risks. For these patients, delaying surgery while attempting to manage symptoms through conservative or regenerative approaches can have reasonable clinical justification.

Recovery after TKR is also substantial. Full recovery commonly takes between 3–6 months, and rehabilitation requires significant physical commitment. For working-age individuals, caregivers, or patients with physically demanding lifestyles, this recovery period can have major practical and financial implications.

Age and frailty may also influence treatment decisions. Some older patients may technically qualify for surgery but still prefer to avoid major orthopaedic procedures due to concerns about prolonged rehabilitation, temporary loss of independence, anaesthesia-related risks, or existing medical comorbidities. In these situations, less invasive treatment strategies are sometimes considered to help support pain management, mobility, and overall quality of life.

What stem cell therapy can and cannot do for a bone-on-bone knee

This is where clinical honesty matters. UC-MSC therapy — the type used at EDNA Wellness — does not regenerate lost cartilage. No current stem cell therapy can rebuild a fully depleted joint surface. Any clinic suggesting otherwise is overclaiming.

What UC-MSC therapy can do, based on published clinical evidence, is modulate the inflammatory environment within the joint, support the remaining tissue, and — in a meaningful subset of patients — reduce pain and improve functional mobility. A 2021 systematic review in Stem Cell Research & Therapy found that MSC injections for knee OA produced significant improvements in pain and function scores, with an acceptable safety profile, particularly in patients with moderate to severe disease.

At EDNA Wellness, all knee cases are reviewed by Dr. Naputt Virasathienpornkul, an orthopedic surgeon specializing in joint preservation and sports medicine, and Dr. Apisit Rattanatanasarn, a board-certified orthopedic surgeon with expertise in joint biomechanics. Cases are evaluated using MRI imaging and clinical assessment before any treatment recommendation is made. If the clinical picture does not support regenerative therapy as a meaningful intervention, patients are told this directly.

Who tends to respond best

Based on clinical evaluation patterns and published research, patients who tend to show more benefit from MSC therapy for advanced knee OA typically share some combination of the following characteristics:

They are in the KL Grade III range rather than fully end-stage Grade IV. Some residual joint space and tissue remain, giving the regenerative environment something to work with.

Their primary complaint is pain and functional limitation rather than structural instability. MSC therapy addresses the inflammatory and biological environment — it does not correct mechanical misalignment or bone deformity.

They are seeking to delay surgery by 2–5 years rather than eliminate it permanently. This is a realistic and clinically reasonable goal. Managing a joint regeneratively until a patient is in their late 60s rather than mid-50s can meaningfully change the surgical calculus.

They have not responded adequately to conservative management (physiotherapy, NSAIDs, corticosteroid or hyaluronic acid injections) but are not yet at the point where function has fully broken down.

What the consultation at EDNA looks like

Patients considering stem cell therapy for bone-on-bone knees are asked to provide recent MRI imaging and any relevant clinical history before their first consultation. This allows the medical team to assess grade of degeneration, presence of meniscal involvement, and whether the structural picture supports a regenerative approach.

If appropriate, EDNA uses fresh, GMP-certified UC-MSCs sourced from a laboratory operating under ISO 9001:2015, OECD GLP, and ISO/IEC 17025:2017 standards, with quality oversight conducted in collaboration with the Thailand Institute of Scientific and Technological Research (TISTR). Procedures are performed under surgeon supervision, with selected cases carried out in partnered private hospital settings when the clinical protocol requires it.

If stem cell therapy is not a suitable option for a patient’s specific presentation, they are referred to appropriate orthopedic care. EDNA Wellness does not position regenerative therapy as a universal solution.

The honest framing

Bone-on-bone knee is a serious condition. Surgery often becomes necessary. But the window between “conservative treatment has stopped working” and “surgery is the only option” is wider than many patients are led to believe — and for the right candidate, that window is worth exploring with a surgeon-led team that can evaluate the evidence alongside the individual.

If you are considering stem cell therapy for advanced knee osteoarthritis and want an honest clinical assessment, EDNA Wellness offers consultations for international patients, including pre-consultation review of imaging and medical history before travel.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

• Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskeletal Disorders. 2008;9:116. https://doi.org/10.1186/1471-2474-9-116
• Guermazi A, Niu J, Hayashi D, et al. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study https://doi.org/10.1136/bmj.e5339
• Pas HI, Winters M, Haisma HJ, et al. Stem cell injections in knee osteoarthritis: a systematic review of the literature. British Journal of Sports Medicine. 2017;51(15):1125–1133. https://doi.org/10.1136/bjsports-2016-096793
• Lopa S, Colombini A, Moretti M, de Girolamo L. Injective mesenchymal stem cell-based treatments for knee osteoarthritis: from mechanisms of action to current clinical evidences https://doi.org/10.1007/s00167-018-5118-9